The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
Abstract
This study utilizes both public and private data sources to estimate clinical phase transition and clinical approval probabilities for drugs in the development pipelines of the 50 largest pharmaceutical firms (by sales). The study examined the development histories of these investigational compounds from the time point at which they first entered clinical testing (1993-2004) through June 2009. The clinical approval success rate in the United States was 16% for self-originated drugs (originating from the pharmaceutical company itself) during both the 1993-1998 and the 1999-2004 subperiods. For all compounds (including licensed-in and licensed-out drugs in addition to self-originated drugs), the clinical approval success rate for the entire study period was 19%. The estimated clinical approval success rates and phase transition probabilities differed significantly by therapeutic class. The estimated clinical approval success rate for self-originated compounds over the entire study period was 32% for large molecules and 13% for small molecules. The estimated transition probabilities were also higher for all clinical phases with respect to large molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Self-citationCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
Self-citationRisks in new drug development: Approval success rates for investigational drugs
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115446 · Cited by 450
Self-citationMonoclonal Antibodies as Innovative Therapeutics
Reichert, J. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786358 · Cited by 265
New drug development in the United States from 1963 to 1999
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115132 · Cited by 251
Self-citationDiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00001 · Cited by 233
Self-citationSuccess rates for new drugs entering clinical testing in the United States
DiMasi, J. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90066-7 · Cited by 184
Self-citationDiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1995) · PharmacoEconomics · doi:10.2165/00019053-199507020-00007 · Cited by 169
Self-citationAssessing the Impact of Protocol Design Changes on Clinical Trial Performance
Getz, K. A., Wenger, J., Campo, R. A., Seguine, E. S., & Kaitin, K. I. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31816b9027 · Cited by 147
Cited by
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,241
Photopharmacology: Beyond Proof of Principle
Velema, W. A., Szymanski, W., & Feringa, B. L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja413063e · Cited by 1,178
Alternatives to antibiotics—a pipeline portfolio review
Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., Foster, S., Gilmore, B. F., Hancock, R. E. W., Harper, D., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00466-1 · Cited by 848
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Seyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Drug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673
Cunningham, C., Ederer, F., & Ma, S. (2021) · Journal of Political Economy · doi:10.1086/712506 · Cited by 452
Deconstructing the Drug Development Process: The New Face of Innovation
Kaitin, K. I. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.293 · Cited by 418
Challenges and opportunities of drug repositioning
Novac, N. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.004 · Cited by 374
Rational Approaches to Improving Selectivity in Drug Design
Huggins, D. J., Sherman, W., & Tidor, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010332 · Cited by 367
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
Organ-on-a chip systems: microengineering to biomimic living systems
Zheng, F., Fu, F., Cheng, Y., Wang, C., Zhao, Y., & Gu, Z. (2016) · Small · doi:10.1002/smll.201503208 · Cited by 338
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
Kaitin, K. I., & DiMasi, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.286 · Cited by 328
Self-citationAddressing Dementia: The OECD Response
OECD (2015) · OECD Health Policy Studies · doi:10.1787/9789264231726-en · Cited by 327
Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
Sultana, A., Zare, M., Thomas, V., Kumar, T. S. S., & Ramakrishna, S. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100134 · Cited by 315
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
Mitsumoto, H., Brooks, B. R., & Silani, V. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70129-2 · Cited by 289
Changing R&D models in research-based pharmaceutical companies
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0838-4 · Cited by 286
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Hyman, S. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003142 · Cited by 260
The Role of Natural Products as Sources of Therapeutic Agents for Innovative Drug Discovery
Dzobo, K. (2022) · Comprehensive Pharmacology · doi:10.1016/b978-0-12-820472-6.00041-4 · Cited by 256
Dhakal, A., McKay, C., Tanner, J. J., & Cheng, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab476 · Cited by 256
The High Cost of Cancer Drugs and What We Can Do About It
Siddiqui, M., & Rajkumar, S. V. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.07.007 · Cited by 255
Risk in vaccine research and development quantified
Pronker, E. S., Weenen, T. C., Commandeur, H., Claassen, E. H. J. H. M., & Osterhaus, A. D. M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057755 · Cited by 253
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Microfluidic 3D models of cancer
Sung, K. E., & Beebe, D. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.002 · Cited by 190
Animal testing and its alternatives—the most important omics is economics
Meigs, L. (2018) · ALTEX · doi:10.14573/altex.1807041 · Cited by 184
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Engineering islets from stem cells for advanced therapies of diabetes
Siehler, J., Blöchinger, A. K., Meier, M., & Lickert, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00262-w · Cited by 125
Lindner, A. U., Concannon, C. G., Boukes, G. J., Cannon, M. D., Llambi, F., Ryan, D., Boland, K., Kehoe, J., McNamara, D. A., Murray, F., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2269 · Cited by 105
Elsallab, M., Bravery, C. A., Kurtz, A., & Abou-El-Enein, M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.035 · Cited by 59
Be open about drug failures to speed up research
Alteri, E., & Guizzaro, L. (2018) · Nature · doi:10.1038/d41586-018-07352-7 · Cited by 50
Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Protein replacement therapies for rare diseases: a breeze for regulatory approval?
Gorzelany, J. A., & de Souza, M. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005007 · Cited by 33
Smucny, J., Stevens, K. E., Olincy, A., & Tregellas, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.77 · Cited by 28
Animal Paradigms to Assess Cognition with Translation to Humans
Wallace, T. L., Ballard, T. M., & Glavis-Bloom, C. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-16522-6_2 · Cited by 26
Beierlein, J. M., McNamee, L. M., Walsh, M. J., Kaitin, K. I., DiMasi, J. A., & Ledley, F. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.001 · Cited by 24
Self-citationBentwich, I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103515 · Cited by 22
MISATO - Machine learning dataset of protein-ligand complexes for structure-based drug discovery
(2023) · doi:10.1101/2023.05.24.542082 · Cited by 18
Expanded access programs: Ethical and practical considerations for Biopharmaceutical Sponsors
Klopfenstein, M., Van Campen, L. E., & Garnett, T. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479015578154 · Cited by 11
“Of those investigational drugs that reach phase III, approximately 40% do not obtain regulatory approval.(3) The primary reason that investigational products are terminated is because they fail to demonstrate a favorable benefit-risk balance for patients.”
BackgroundCognitive go/No-go decision-making criteria in Alzheimer’s disease drug development
Wessels, A. M., Edgar, C. J., Nathan, P. J., Siemers, E. R., Maruff, P., & Harrison, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.012 · Cited by 7
Metadata
- Authors
- DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-02-03
- Volume
- 87
- Issue
- 3
- Pages
- 272-277
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2065812641
- Cited by
- 845
- References
- 14
- FWCI
- 112.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.